WO2022191551A1 - Composition comprenant du cannabigérol - Google Patents

Composition comprenant du cannabigérol Download PDF

Info

Publication number
WO2022191551A1
WO2022191551A1 PCT/KR2022/003210 KR2022003210W WO2022191551A1 WO 2022191551 A1 WO2022191551 A1 WO 2022191551A1 KR 2022003210 W KR2022003210 W KR 2022003210W WO 2022191551 A1 WO2022191551 A1 WO 2022191551A1
Authority
WO
WIPO (PCT)
Prior art keywords
hair
composition
lotion
ginseng
extract
Prior art date
Application number
PCT/KR2022/003210
Other languages
English (en)
Korean (ko)
Inventor
권민정
진무현
이소영
Original Assignee
주식회사 엘지생활건강
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 엘지생활건강 filed Critical 주식회사 엘지생활건강
Publication of WO2022191551A1 publication Critical patent/WO2022191551A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
    • A61K8/988—Honey; Royal jelly, Propolis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/592—Mixtures of compounds complementing their respective functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Definitions

  • the present invention cannabigerol (Cannabigerol); and isopulegol, ginseng extract, centella asiatica extract, niacinamide, hyaluronic acid, vitamin C, panthenol, adenosine, cedrol, Ginseng saponin, and one or more selected from the group consisting of propolis; a composition comprising, specifically, for moisturizing the skin including the composition as an active ingredient; for anti-inflammatory or skin soothing; Or it relates to a composition for whitening.
  • Cannabigerol is a trace amount of active ingredient that can be obtained from the seeds of cannabis sativa. Cannabigerol is not a psychotropic substance and is known to have various effects.
  • the present inventors have prepared cannabigerol; isopulegol, ginseng extract, centella asiatica extract, niacinamide, hyaluronic acid, When combined with one or more selected from the group consisting of vitamin C (vitamin C), panthenol, adenosine, cedrol, ginseng saponin, and propolis, HAS than using each component alone
  • vitamin C vitamin C
  • panthenol panthenol
  • adenosine cedrol
  • ginseng saponin ginseng saponin
  • propolis HAS than using each component alone
  • the present invention was completed by confirming that -2 (Hyaluronan Synthase 2) or AQP3 (Aquaporin 3) expression increase, NO production inhibition, and tyrosinase activity inhibition effects were significantly superior.
  • the present invention is a cosmetic, for a quasi-drug composition, cannabigerol (Cannabigerol); and isopulegol, ginseng extract, centella asiatica extract, niacinamide, hyaluronic acid, vitamin C, panthenol, adenosine, cedrol, It provides a composition comprising ginseng saponin, and one or more selected from the group consisting of propolis as an active ingredient.
  • cannabigerol (Cannabigerol); and isopulegol, ginseng extract, centella asiatica extract, niacinamide, hyaluronic acid, vitamin C, panthenol, adenosine, cedrol, It provides a skin moisturizing, anti-inflammatory or skin soothing, or skin whitening method comprising the step of treating the skin with a composition comprising ginseng saponin, and propolis as an active ingredient.
  • cannabigerol (Cannabigerol); and isopulegol, ginseng extract, centella asiatica extract, niacinamide, hyaluronic acid, vitamin C, panthenol, adenosine, cedrol, It provides a skin moisturizing, anti-inflammatory or skin soothing, or skin whitening method comprising administering to a subject a composition comprising ginseng saponin, and propolis as an active ingredient.
  • skin moisturizing, anti-inflammatory or skin soothing, or skin whitening cosmetic In order to achieve the above object, skin moisturizing, anti-inflammatory or skin soothing, or skin whitening cosmetic; Or quasi-drugs; Cannabigerol for manufacturing; and isopulegol, ginseng extract, centella asiatica extract, niacinamide, hyaluronic acid, vitamin C, panthenol, adenosine, cedrol, It provides the use of a composition comprising ginseng saponin, and propolis as an active ingredient.
  • composition according to the present invention has an effect of increasing the expression of HAS-2 or AQP3, inhibiting the production of NO, and inhibiting tyrosinase activity, and has a synergistic effect due to the combination of the present invention, as a cosmetic or quasi-drug composition can be used effectively.
  • Increased expression of HAS-2 or AQP3, inhibition of NO production, and inhibition of tyrosinase activity are all more effective than cannabigerol alone, isopulegol, ginseng extract, centella asiatica extract, niacinamide (niacinamide), hyaluronic acid (hyaluronic acid), vitamin C (vitamin C), panthenol (panthenol), adenosine (adenosine), cedrol (cedrol), one or more selected from the group consisting of ginseng saponin and propolis; It was confirmed that a synergistic effect occurred when combined with
  • the present invention cannabigerol (Cannabigerol); and
  • cannabigerol (Cannabigerol); and isopulegol, ginseng extract, centella asiatica extract, niacinamide, hyaluronic acid, vitamin C, panthenol, adenosine, cedrol, It provides a skin moisturizing, anti-inflammatory or skin soothing, or skin whitening method comprising the step of treating the skin with a composition comprising ginseng saponin, and propolis as an active ingredient.
  • cannabigerol (Cannabigerol); and isopulegol, ginseng extract, centella asiatica extract, niacinamide, hyaluronic acid, vitamin C, panthenol, adenosine, cedrol, It provides a skin moisturizing, anti-inflammatory or skin soothing, or skin whitening method comprising administering to a subject a composition comprising ginseng saponin, and propolis as an active ingredient.
  • the active ingredients (Cannabigerol, isopulegol, ginseng extract, Centella asiatica extract, niacinamide, hyaluronic acid, vitamin C (vitamin C), panthenol (panthenol), Adenosine (adenosine), cedrol (cedrol), ginseng saponin, and propolis) Legally permitted commercial products or commercial ingredients of the active ingredient may be used.
  • the "extract" of the present invention is an extract obtained by the extraction treatment of the plant material, a diluted or concentrated liquid of the extract, a dried product obtained by drying the extract, a prepared or purified product of the extract, or a mixture thereof, such as the extract itself and extracts of all formulations that can be formed using the extract.
  • the extract of the present invention may be prepared and used in the form of a dry powder after extraction.
  • any part of ginseng or Centella asiatica such as an outpost, leaf, root, fruit, stem, etc. of ginseng or Centella asiatica may be used.
  • the "ginseng saponin” of the present invention is a saponin present in the ginseng extract before purification, and refers to all of the saponin contained in ginseng, a substance represented by saponin, a substance to be changed to saponin, or a substance presumed to be saponin.
  • the saponins contained in ginseng are panaxadiol-based saponins (Ra1, G-Ra2, G-Ra3, G-Rb1, G-Rb2, Rb3, G-Re, G-Rd, G-Rs1, G-Rs2, Rg3 ( 20 S), G-Rg3(20R), G-Rh2, G-Rs3, Rs4, G-Rg5, G-F4,Q-R1, N-R4, Rg6, etc.)
  • Panaxatriol-based saponins Ros, Rf , Rg1, Rg2(20 S), Rg2(20 R), Rh1(20 S), Rh2(20 R), 20-glc-Rf, N-R1, Rh4, Rf2, etc.
  • oleic saponins G-R, etc.
  • G-R, etc. etc.
  • the ginseng saponin of the present invention may be a mixture of several types of ginseng saponins mentioned above or not mentioned, or may be a single type of ginseng saponin, and ginsenoside, pseudoginsenoside, or its It may be other ginseng saponins.
  • the composition may be a cosmetic or quasi-drug.
  • the cosmetics include lotion, essence, lotion, cream, pack, gel, powder, foundation, balm, ointment, detergent, hair shampoo, hair tonic, hair conditioner, hair lotion, hair nourishing lotion, hair treatment, hair essence , hair pack, hair liquid, non-aerosol mousse, non-aerosol spray, aerosol mousse or aerosol spray formulation, but is not limited thereto.
  • “Moisturizing skin” of the present invention means to increase the feeling of moisture in the skin and to maintain a moist state by suppressing moisture loss.
  • the skin moisturizing effect was confirmed by increasing the expression of HAS-2 (Hyaluronan Synthase 2) or AQP3 (Aquaporin 3).
  • composition may have an effect of increasing the expression of HAS-2 or AQP3.
  • anti-inflammatory refers to inhibiting inflammation, and the inflammation is one of the defense responses of a living tissue to a certain stimulus, and refers to a complex lesion that combines three types: tissue deterioration, circulatory disorder and exudation, and tissue proliferation. More specifically, inflammation is part of innate immunity, and as in other animals, human innate immunity recognizes patterns on the surface of cells that are specific to pathogens. Phagocytes recognize cells with such a surface as non-self and attack pathogens. If pathogens break through the body's physical barriers, an inflammatory response occurs. The inflammatory response is a non-specific defense action that creates a hostile environment for microorganisms that invade the wound site.
  • the white blood cells responsible for the early stage immune response flock and express cytokines. Therefore, the expression level of intracellular cytokines is an indicator of inflammatory response activation.
  • skin diseases associated with inflammation include atopic dermatitis, psoriasis, erythematous diseases triggered by radiation, chemicals, burns, etc., acid burns, bullous dermatosis, lichenoid type disease, itching due to allergy, seborrheic eczema, acne on roses, pemphigus vulgaris, erythema multiforme, erythema nodosum, balanitis, vulvitis, inflammatory hair loss such as alopecia areata, cutaneous T-cell lymphoma, and the like.
  • the anti-inflammatory effect of the present invention for example, it may have an effect of improving skin troubles such as acne.
  • the anti-inflammatory hair loss such as alopecia areata, cutaneous T-cell lymphoma, and the like.
  • skin soothing means alleviating or reducing inflammation, or itching, redness, pain, burning, or swelling caused by inflammation.
  • the skin soothing may mean a skin soothing effect by reducing or inhibiting inflammation.
  • the composition may have an effect of inhibiting the production of NO.
  • Whitening of the present invention means not only to brighten skin tone by inhibiting the synthesis of melanin, but also to inhibit or prevent melanin deposition (hyperpigmentation), to relieve or to relieve freckles caused by UV rays, hormones, or heredity. It means any action that improves.
  • melanin deposition hyperpigmentation
  • tyrosinase activity was confirmed.
  • the composition may have a tyrosinase activity inhibitory effect.
  • the "cosmetics composition” of the present invention may be in the form of general emulsified formulations and solubilized formulations.
  • lotions such as flexible lotions or nourishing lotions, emulsions such as facial lotions and body lotions, creams such as nourishing creams, moisture creams, and eye creams, essences, cosmetic ointments, balms, sprays, gels, packs, sunscreens , makeup base, liquid type, solid type or spray type foundation, powder, cleansing cream, cleansing lotion, makeup remover such as cleansing oil, cleansing agent such as cleansing foam, soap, body wash, etc., but is limited thereto it's not going to be
  • the cosmetic includes a fatty substance, an organic solvent, a solubilizer, a thickening agent and a gelling agent, an emollient, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant, water, Ionic or nonionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic actives, lipid vesicles or any conventionally used in cosmetics It may contain adjuvants commonly used in the field of cosmetology such as other ingredients of
  • the cosmetic formulation may include a relatively high concentration of the composition of the present invention in the case of a wash-off type cosmetic such as a makeup remover or a detergent in which the active ingredient stays on the skin within a short period of time.
  • a wash-off type cosmetic such as a makeup remover or a detergent
  • leave-on type cosmetics such as lotions, emulsions, creams, and essences
  • the composition of the present invention at a lower concentration than the wash-off type cosmetics. would be free to include.
  • the composition comprises 0.000001% to 10% by weight (preferably 0.000001% to 1% by weight) of the composition of the present invention based on the total weight of the composition.
  • composition of the present invention contains less than 0.000001% by weight of the composition of the present invention, sufficient moisturizing, anti-inflammatory or skin soothing and whitening effects cannot be expected, and when it contains more than 10% by weight, unwanted reactions such as allergies This is to prevent this from occurring or there may be problems with skin safety.
  • the "quasi-drug composition" of the present invention refers to an article that is used for the purpose of diagnosing, treating, alleviating, treating or preventing diseases of humans or animals, but has a milder effect on the human body than pharmaceuticals, and is not an instrument, machine or device among articles It means a composition for articles other than instruments, machines, or devices among articles used for the purpose of pharmacologically affecting the structure and function of humans or animals. Except for articles used for pharmaceutical purposes according to the Pharmaceutical Affairs Act, one embodiment may include, but is not limited to, external preparations for skin, personal care products, or preparations for internal use. Components and the like may be appropriately selected from conventional techniques known in the art.
  • compositions of the present invention may be included in the composition of the present invention, preferably within a range not exceeding the maximum amount specified in the norms stipulated by the respective national governments.
  • the cosmetic composition of the present invention may be added to the cosmetic composition of the present invention within a range that does not exceed the maximum amount specified in the Cosmetic Safety Act stipulated by each country or the “Cosmeceutical Safety Technical Specification” stipulated by the Chinese government. may be included.
  • Ginseng (Panax ginseng) roots were extracted with 70% ethanol aqueous solution corresponding to 30 times the mass at room temperature for 3 days, and then filtered under reduced pressure. The filtered extract was concentrated and dried with a rotary evaporator (Buchi, Switzerland) to prepare an extract.
  • Centella asiatica leaves were extracted with 70% ethanol aqueous solution corresponding to 30 times the mass at room temperature for 3 days, and then filtered under reduced pressure. The filtered extract was concentrated and dried with a rotary evaporator (Buchi, Switzerland) to prepare an extract.
  • the prepared ginseng extract was extracted three times with a solvent in which equal amounts of water and saturated butanol were mixed, and the saturated butanol layers were combined and concentrated under reduced pressure using a rotary evaporator (Buchi, Switzerland).
  • Example 1 Cannabigerol (CBG)
  • Example 2 isopuregol
  • Ginseng Extract Example 4 Centella asiatica extract
  • Niacinamide Example 6 hyaluronic acid
  • Example 7 vitamin c
  • Example 8 panthenol
  • Example 9 adenosine
  • Example 10 cedrol
  • Example 11 ginseng saponin
  • Example 12 propolis
  • Fibroblasts were seeded and cultured at a concentration of 2-5 x 10 4 cells/ml using DMEM (Dulbecco's Modified Eagle's Medium, Gibco) supplemented with 10% FBS (Fetal Bovine Serum) as a basal medium. After the cultured cells were transferred to DMEM medium not containing 10% FBS and calcium ions, Examples and Comparative Examples were treated alone or in combination at concentrations corresponding to Table 2 below and cultured for 24 hours.
  • DMEM Dulbecco's Modified Eagle's Medium, Gibco
  • FBS Fetal Bovine Serum
  • TaqMan® Universal Master Mix II (Thermo Fisher, catalog number 4440043) with TaqMan® GeneExpression Assays (Thermo Fisher, catalog number 4331348), HAS2 primer (5'-CCCAAAATGTGAAGCTTGGT -3'), AQP3 primer (5'-AGACAGCCCCTTCAGGATTT-3' ) was used. Quantitative real time PCR was performed using the StepOnePlus® Realtime PCR System (Applied Biosystems, catalog number 4376600). The experimental results were calculated using the ⁇ Ct method based on the housekeeping gene Glyceraldehyde-3-phosphate dehydrogenase (GAPDH, 5'-TGCACCACCAACTGCTTAGC-3').
  • Example 1 0.0001% 8.54 7.66
  • Example 2 0.001% 2.25 29.81 11.40 25.14
  • Example 3 0.01% 16.73 43.15 4.49 19.06
  • Example 4 0.01% 15.00 32.95 2.51 20.93
  • Example 5 0.001% 6.72 18.10 8.97 18.14
  • Example 6 0.001% 6.41 33.79 3.78 12.76
  • Example 7 0.001% 18.32 46.31 7.88 20.28
  • Example 8 0.001% 3.17 16.95 2.48 20.53
  • Example 9 0.001% 2.51 31.24 6.23 22.25
  • Example 10 0.001% 8.06 22.67 0.98 16.59
  • Example 11 0.01% 5.83 44.25 4.26 20.72
  • Example 12 0.01% 6.09 35.54 4.90 23.94
  • the NO production inhibitory effect was measured using a mouse macrophage cell line, Raw 264.7 cells (ATCC, catalog number CRL-2788). 10% FBS was added to DMEM and used as a growth medium. Raw264.7 cells were seeded at a concentration of 1 to 2 x 10 5 cells/ml and cultured in a 5% CO 2 incubator for one day. After removing the medium and starvation with a serum-free medium for 12 hours, Examples and Comparative Examples were treated alone or in combination at the concentrations corresponding to Table 3 below and pre-treated for 30 minutes.
  • Example 1 sample number sample concentration NO production inhibition ability (%) Use of each sample alone Combination with Example 1 Comparative Example 1 0.00 Comparative Example 2 53.02
  • Example 1 0.0001% 26.21
  • Example 2 0.001% 13.50 59.04
  • Example 3 0.01% 27.18 62.38
  • Example 4 0.01% 27.53 57.73
  • Example 5 0.001% 9.84 53.67
  • Example 6 0.001% 24.09 60.74
  • Example 7 0.001% 37.81 66.90
  • Example 8 0.001% 21.42 57.97
  • Example 9 0.001% 24.12 60.91
  • Example 10 0.001% 12.47 52.72
  • Example 11 0.01% 19.42 60.70
  • Example 12 0.01% 25.63 57.80
  • MNT-1 melanoma cells (ATCC, catalog number CRL-3450) were seeded in DMEM medium containing 10% FBS at a concentration of 1 to 2 x 10 5 cells/ml and cultured for 24 hours. Examples and Comparative Examples were treated alone or in combination on melanocytes cultured at the concentration corresponding to Table 4 below and cultured for 72 hours, and then the cells were recovered. After centrifugation at 13,000 rpm for 1 minute and removing the supernatant, 300 ⁇ l of 0.5% triton X-100 solution was added to the pellet to lyse the cells.
  • Example 1 sample number sample concentration Tyrosinase activity (%) Use of each sample alone Combination with Example 1 Comparative Example 1 100 Comparative Example 2 57.94 Example 1 0.0001% 89.75 Example 2 0.001% 98.23 72.79 Example 3 0.01% 89.34 70.10 Example 4 0.01% 80.93 61.28 Example 5 0.001% 77.25 60.99 Example 6 0.001% 88.98 66.99 Example 7 0.001% 73.84 51.77 Example 8 0.001% 98.59 75.48 Example 9 0.001% 77.91 50.05 Example 10 0.001% 95.68 76.77 Example 11 0.01% 84.42 71.39 Example 12 0.01% 92.26 77.44

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

Abstract

La présente invention se rapporte à une composition comprenant : du cannabigérol ; et un ou plusieurs composants choisis dans le groupe constitué par l'isopulégol, un extrait de ginseng, un extrait de Centella asiatica, le niacinamide, l'acide hyaluronique, la vitamine C, le panthénol, l'adénosine, le cédrol, la saponine brute de ginseng et la propolis et, plus particulièrement, à une composition hydratante pour la peau, anti-inflammatoire ou de soin apaisant pour la peau et de blanchiment comprenant la composition en tant que matière active. De plus, il a été confirmé qu'en termes de tous les effets hydratants, anti-inflammatoires ou apaisant la peau et de blanchiment, la composition selon la présente invention avait un effet synergique une fois combinée à un ou plusieurs composants choisis dans le groupe constitué par l'isopulégol, un extrait de ginseng, un extrait de Centella asiatica, le niacinamide, l'acide hyaluronique, la vitamine C, le panthénol, l'adénosine, le cédrol, la saponine brute de ginseng et la propolis, par comparaison au cannabigérol seul.
PCT/KR2022/003210 2021-03-08 2022-03-07 Composition comprenant du cannabigérol WO2022191551A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2021-0030241 2021-03-08
KR20210030241 2021-03-08

Publications (1)

Publication Number Publication Date
WO2022191551A1 true WO2022191551A1 (fr) 2022-09-15

Family

ID=83227945

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/003210 WO2022191551A1 (fr) 2021-03-08 2022-03-07 Composition comprenant du cannabigérol

Country Status (2)

Country Link
KR (1) KR20220126653A (fr)
WO (1) WO2022191551A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115778828A (zh) * 2023-02-10 2023-03-14 安婕妤化妆品科技股份有限公司 一种含有富勒烯的化妆品组合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10206888B2 (en) * 2017-06-06 2019-02-19 Cmg Partners, Inc. Cannabis-based therapeutic product for treatment of chronic pain
KR20190034576A (ko) * 2016-08-03 2019-04-02 젤다 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 카나비스 조성물
US20200188325A1 (en) * 2015-02-16 2020-06-18 Axim Biotechnologies, Inc. Cosmetic and topical compositions comprising cannabigerol
WO2020249184A1 (fr) * 2019-06-11 2020-12-17 Symrise Ag Synthèse et purification de cannabigérol et son utilisation
KR20210008327A (ko) * 2018-01-13 2021-01-21 트루티바 인코포레이티드 노화 방지 및 피부 톤 미백 조성물 및 이를 위한 방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200188325A1 (en) * 2015-02-16 2020-06-18 Axim Biotechnologies, Inc. Cosmetic and topical compositions comprising cannabigerol
KR20190034576A (ko) * 2016-08-03 2019-04-02 젤다 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 카나비스 조성물
US10206888B2 (en) * 2017-06-06 2019-02-19 Cmg Partners, Inc. Cannabis-based therapeutic product for treatment of chronic pain
KR20210008327A (ko) * 2018-01-13 2021-01-21 트루티바 인코포레이티드 노화 방지 및 피부 톤 미백 조성물 및 이를 위한 방법
WO2020249184A1 (fr) * 2019-06-11 2020-12-17 Symrise Ag Synthèse et purification de cannabigérol et son utilisation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115778828A (zh) * 2023-02-10 2023-03-14 安婕妤化妆品科技股份有限公司 一种含有富勒烯的化妆品组合物

Also Published As

Publication number Publication date
KR20220126653A (ko) 2022-09-16

Similar Documents

Publication Publication Date Title
KR102257524B1 (ko) 피부 진정 및 재생효과를 지니는 병풀 유래 엑소좀 함유 피부 개선용 화장료 조성물
EP2889027B1 (fr) Préparation orale, préparation d'injection, préparation externe pour la peau et procédé cosmétique pour prévenir ou améliorer les rides
US20090028969A1 (en) Compostion for treating skin
Devi et al. Study of antioxdant, antiinflammatory and woundhealing activity of extracts of Litsea glutinosa
WO2011122869A2 (fr) Composition cosmétique comprenant du coumestrol ou un extrait de fèves contenant du coumestrol, pour les soins de la peau
DE102008059523A1 (de) Kosmetische Mixtur, die Ascorbinsäure-2-Glucosid und Ergothionein enthält
KR101928797B1 (ko) 컴파운드 ｋ를 함유하는 피부 외용제 조성물
KR102021463B1 (ko) 진세노사이드 Rg3를 함유하는 피부 외용제 조성물
KR20130088912A (ko) 텐저레틴 및 ｅｇｃｇ를 함유하는 피부 외용제 조성물
WO2017043670A1 (fr) Composition cosmétique contenant un extrait de cédrat
KR101460569B1 (ko) 진세노사이드 ｆ２를 유효 성분으로 포함하는 주름개선, 피부미백 및 여드름 개선용 화장료 조성물
US10555894B2 (en) Plant extract comprising sucrose esters as an active agent for use in cosmetic, dermatological or nutricosmetic composition
WO2017217695A1 (fr) Composition comprenant l'alpha-garcinia mangostana, le bêta-garcinia mangostana, le gamma-garcinia mangostana, ou le composé gartanin utilisé comme ingrédient efficace pour atténuer les rides de la peau ou pour hydrater la peau
WO2022191551A1 (fr) Composition comprenant du cannabigérol
WO2013077569A1 (fr) Composition de traitement cutané à application topique comprenant un extrait de dendranthema indicum
KR20100074688A (ko) 조직배양한 에키네시아 부정근 추출물을 포함하는 화장료 조성물 및 이의 제조 방법
WO2013115456A1 (fr) Aliment, substance cosmétique, ou composition pharmaceutique contenant un extrait supercritique de gingembre et un extrait de résidu de persil japonais fermenté
KR20100018139A (ko) 돌나물 추출물 및 리포익산-ｐｅｇ 콘쥬게이트를 함유하는피부외용제 조성물
KR101430636B1 (ko) 진세노사이드 Ｒｈ2 및 진세노사이드 Ｒｇ3를 함유하는 기능성 화장료 조성물
JP3998085B2 (ja) ヒアルロン酸量増加促進剤
KR102024572B1 (ko) 진세노사이드 Rf를 함유하는 피부 외용제 조성물
KR101934564B1 (ko) 발아 녹차씨 추출물을 함유하는 피부 외용제 조성물
KR102525579B1 (ko) 쌀, 갈대, 옥촉서예, 당아욱 및 알로에추출물을 포함하는 피부 보호용 화장료 조성물
KR20090085844A (ko) 약용식물 추출물을 포함하는 피부 염증 완화용 화장료조성물
WO2016171482A1 (fr) Composition cosmétique comprenant un extrait d'apitoxine, et son procédé de fabrication

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22767447

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22767447

Country of ref document: EP

Kind code of ref document: A1